Zentalis Pharmaceuticals (ZNTL) investor relations material

Executive summary

• Focused on late-stage clinical development of azenosertib, a WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), with ongoing pivotal trials, completion of DENALI Part 2a/2b enrollment, and initiation of ASPENOVA Phase 3 trial.

• Regulatory alignment with FDA supports accelerated approval pathway for azenosertib, with topline DENALI Part 2 data expected in 1H 2027.

• No products approved or revenue from product sales; operations funded by equity offerings and collaborations.

• Strategic restructuring in 2025 reduced workforce by 40% to extend cash runway and prioritize azenosertib development.

• Expanded commercial capabilities with new board and executive appointments to support future product launch.

Financial highlights

• Net loss for Q2 2026 was $42.3 million, or $0.59 per share, up from $26.9 million, or $0.37 per share, in Q2 2025.

• Research and development expenses rose to $35.2 million in Q2 2026 (from $27.6 million), mainly due to a $7.0 million milestone payment and increased clinical trial costs.

• Cash, cash equivalents, and marketable securities totaled $174.6 million as of June 30, 2026, down from $245.9 million at December 31, 2025.

• Operating expenses for Q2 2026 were $44.4 million, up from $36.1 million in Q2 2025.

• Accumulated deficit reached $1.3 billion as of June 30, 2026.

Outlook and guidance

• Existing cash resources expected to fund operations into late 2027, but additional capital will be needed for full development and commercialization.

• Topline readout from the pivotal DENALI Part 2 trial anticipated in the first half of 2027; ASPENOVA Phase 3 trial enrollment ongoing.

• Ongoing efforts to develop a companion diagnostic for patient selection in PROC.